N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: N-Butyldeoxynojirimycin (NB-DNJ), an inhibitor of HIV gp120 folding, was assessed as a broadly active therapy for the treatment of HIV/AIDS. Furthermore, to reduce the effective dose necessary for antiviral activity, NB-DNJ was encapsulated inside liposomes and targeted to HIV-infected cells. METHODS: Thirty-one primary isolates of HIV (including drug-resistant isolates) were cultured in peripheral blood mononuclear cells to quantify the effect of NB-DNJ on viral infectivity. pH-sensitive liposomes capable of mediating the intracellular delivery of NB-DNJ inside peripheral blood mononuclear cells were used to increase drug efficacy. RESULTS: NB-DNJ decreased viral infectivity with a single round of treatment by an average of 80% in HIV-1-infected and 95% in HIV-2-infected cultures. Two rounds of treatment reduced viral infectivity to below detectable levels for all isolates tested, with a calculated IC50 of 282 and 211 micromol/l for HIV-1 and HIV-2, respectively. When encapsulated inside liposomes, NB-DNJ inhibited HIV-1 with final concentrations in the nmol/l range (IC50 = 4 nmol/l), a 100 000-fold enhancement in IC50 relative to free NB-DNJ. Targeting liposomes to the gp120/gp41 complex with a CD4 molecule conjugated to the outer bilayer increased drug/liposome uptake five-fold in HIV-infected cells compared with uninfected cells. NB-DNJ CD4 liposomes demonstrated additional antiviral effects, reducing viral secretion by 81% and effectively neutralizing free viral particles to prevent further infections. CONCLUSION: The use of targeted liposomes encapsulating NB-DNJ provides an attractive therapeutic option against all clades of HIV, including drug-resistant isolates, in an attempt to prevent disease progression to AIDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiviral effects of an iminosugar derivative on flavivirus infections
Wu, S.-F., Lee, C.-J., Liao, C.-L., Dwek, R. A., Zitzmann, N., & Lin, Y.-L. (2002) · Journal of Virology · doi:10.1128/jvi.76.8.3596-3604.2002 · Cited by 220
Self-citationFischer, P. B., Collin, M., Karlsson, G. B., James, W., Butters, T. D., Davis, S. J., Gordon, S., Dwek, R. A., & Platt, F. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5791-5797.1995 · Cited by 155
Self-citation
Cited by
Emerging principles for the therapeutic exploitation of glycosylation
Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N., & Dwek, R. A. (2014) · Science · doi:10.1126/science.1235681 · Cited by 447
Self-citationIminosugars past, present and future: Medicines for tomorrow
Horne, G., Wilson, F. X., Tinsley, J., Williams, D. H., & Storer, R. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2010.08.017 · Cited by 320
An overview of nanoparticles in drug delivery: Properties and applications
Hsu, C.-Y., Rheima, A. M., Kadhim, M. M., Ahmed, N. N., Mohammed, S. H., Abbas, F. H., Abed, Z. T., Mahdi, Z. M., Abbas, Z. S., Hachim, S. K., et al. (2023) · South African Journal of Chemical Engineering · doi:10.1016/j.sajce.2023.08.009 · Cited by 165
Therapeutic applications of iminosugars: Current perspectives and future opportunities
Horne, G., & Wilson, F. X. (2011) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-381290-2.00004-5 · Cited by 87
Pollock, S., Nichita, N. B., Böhmer, A., Radulescu, C., Dwek, R. A., & Zitzmann, N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009445107 · Cited by 76
Self-citation
Metadata
- Authors
- Pollock, S., Dwek, R. A., Burton, D. R., & Zitzmann, N.
- Venue
- AIDS
- Published
- 2008-10-01
- Volume
- 22
- Issue
- 15
- Pages
- 1961-1969
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2008270141
- Cited by
- 67
- References
- 2
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. https://app.cochat.ai/papers/10.1097/qad.0b013e32830efd96
- The paper
- Pollock, S., Dwek, R. A., Burton, D. R., & Zitzmann, N. (2008). N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery. AIDS. https://doi.org/10.1097/qad.0b013e32830efd96
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.